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Background
Nanocarbon materials attract growing interest as a platform for drug development, 
including anticancer preparations (Dellinger et  al. 2013; Yang et  al. 2014; Chen et  al. 
2015). Fullerene–biomolecule conjugates exhibit a very high antineoplastic efficiency. 
For example, the chemical attachment of anticancer preparations such as Paclitaxel 
and Doxorubicin (Dox) to  C60 fullerene results in an improvement of these drugs’ 
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pharmacokinetics and increases their therapeutic efficacy (Liu et  al. 2011; Magou-
las et  al. 2015; Prylutska et  al. 2015). Previous investigations from our research group 
revealed that pristine  C60 fullerene possesses a potent anticancer activity per se (Prylut-
ska et al. 2011a, b; Lynchak et al. 2017). In addition, we have demonstrated that conju-
gation of Dox and Cisplatin (Cis) with the  C60 fullerene led to significant increase in its 
toxicity toward various human tumor cell lines in vitro and greatly enhances the inhibi-
tory effect of these drugs on the growth of Lewis lung carcinoma in vivo (Prylutska et al. 
2015a, b, 2017 Panchuk et al. 2015). It is well documented that the underlying mecha-
nism of antineoplastic effect of  C60 fullerene-based nanoformulations is related with the 
combination of the direct effect on tumor cells (modulation of oxidative stress, apop-
tosis, necrosis, and autophagy), their effect on tumor microenvironment (reduction of 
the blood supply to tumor tissues), and activation of the host immune system (Dellinger 
et al. 2013; Harhaji et al. 2007; Shi and Li 2012).
There are limited and controversial data concerning immunomodulatory effects of 
 C60 fullerenes. Liu et al. (2009) have shown that  C60 fullerene and its derivatives exert 
potent immunomodulatory pro-inflammatory activities: increase TNFα production 
and enhance cell immune response, and show almost no adverse effect to the viability 
of immune cells. Fujita et  al. (2009) revealed that genes involved in the inflammatory 
response, oxidative stress, metalloendopeptidase activity, as well as MHC expression 
were upregulated in immune cells after the exposure to  C60 fullerene. Zogovich et  al. 
(2009) have reported a significant increase in splenocyte production of the immunoreg-
ulatory free radical nitric oxide (NO) after the treatment with  C60 fullerene. A special 
attention in the analysis of  C60 fullerene immunomodulatory properties is given to their 
influence on phagocytes.
Phagocytes are credited with a crucial role in the development of the immune 
response. Professional phagocytes (monocytes, dendritic cells, macrophages, neu-
trophils, and mast cells) constitute the first line of cellular immune defense. These 
cells are important players in the antitumor protection and are the link between the 
innate and adaptive immunity (Murray and Wynn 2011; Galdiero et al. 2013; Sica et al. 
2015). Monocytes/macrophages and neutrophils activate, orient, and regulate adap-
tive responses. These cells are characterized by high plasticity and can possess different 
metabolic profiles, depending on the activating stimuli. There are two main diametrally 
opposite polarizational state of macrophages/neutrophils (not excepting numerous 
intermediate metabolic states): classical (M1 and N1, respectively) and alternative (M2 
and N2, respectively). The main distinctive features of classically polarized phagocytes 
are the generations of effector molecules (reactive oxygen and nitrogen species) and 
cytokines (TNFα, IL1β, IL6, etc.) participating in the inflammation and promotion of 
Th1 immune response. These cells mediate immune defense against intracellular patho-
gens and malignant tumors. Characteristic features of alternatively polarized phagocytes 
are their participations in the resolution of inflammation, tissue repair, and switching 
of adaptive immune response to Th2 profile. These cells express high levels of receptors 
involved in endocytosis, produce anti-inflammatory cytokines, and metabolize arginine 
to ornithine and polyamines. Alternatively, polarized phagocytes can possess immuno-
suppressive activity, participate in tissue remodeling, and promote tumor growth and 
angiogenesis (Locati et al. 2013; Okabe and Medzhitov 2016; Egners et al. 2016).
Page 3 of 22Skivka et al. Cancer Nano             (2018) 9:8 
Regardless of the route of  C60 fullerene administration chosen, phagocytes are the 
first cells of the body immune system, which are influenced by these nanoformulations. 
Therefore, a greater understanding of interactions between  C60 fullerene and phagocyte 
will enable the creation of better predictive models of their therapeutic efficacy as well 
as adverse outcomes following exposure. Russ et  al. (2016) suggested that  C60 fuller-
ene’s effect on phagocyte signaling is achieved through endocytosis/pinocytosis as well 
as passive diffusion of this nanostructure. According to the limited literature data avail-
able, the character of the  C60 fullerene’s influence on phagocytes depends on their geo-
metric structure, dose, duration of exposure, and the initial functional state of the cells. 
 C60 fullerene and their derivatives at low concentrations exerted mainly negative effect 
on the functions of nonsensitized macrophages in vitro by inhibiting the myeloperoxi-
dase activity, and suppressed the expression of CD54 involved in the adhesion (Vesnina 
et  al. 2011; Pirutin et  al. 2012). Inhibitory effect of  C60 fullerene on pro-inflammatory 
(classically)-activated macrophages was described in rats with experimental adjuvant-
induced arthritis (Vesnina et al. 2012). Many authors are unison in their opinions that 
 C60 fullerenes dramatically affect the phagocyte oxidative metabolism and can even 
induce apoptosis of macrophage by changing the mitochondrial membrane potential 
(Santos et al. 2014; Zhang et al. 2015; Yu et al. 2015). Based on our previous experience, 
in vivo anticancer effects of  C60 fullerene and  C60 + Dox nanocomplexes are accompa-
nied by the increase of macrophage oxygen-dependent cytotoxicity toward authologic 
tumor cells (Prylutska et al. 2015). In addition, our previous results revealed direct toxic 
effects of  C60 fullerene and its nanocomplexes with anticancer drugs on transformed 
leukocytes including myelocytic cells (Panchuk et al. 2015; Scharff et al. 2008; Fransk-
evych et al. 2015).
The main aim of this study was to investigate the effect of  C60 fullerene and its nano-
complexes with anticancer drugs on human phagocyte metabolic profile in vitro. Poten-
tial mechanisms of this effect have been analyzed using docking experiments of direct 
interactions between the  C60 fullerene and phagocyte pattern-recognition receptors as 
well as cytochrome p450 (CYP). A study of the effect of  C60 fullerene and its nanocom-
plexes with anticancer preparations on pro-monocytic, human myeloid leukemia cell 
line U937 was also performed to explore the potential application of  C60 fullerene in the 
therapy of acute myelocytic leukemia.
Methods
Preparation of  C60 fullerene aqueous colloid solution
The pristine  C60 fullerene aqueous colloid solution  (C60FAS; final concentration 0.15 mg/
ml) used in the experiments was prepared according to the protocols developed previ-
ously (Scharff et al. 2004; Prylutskyy et al. 2014; Ritter et al. 2015).
Preparation of  C60 + Cis and  C60 + Dox nanocomplexes
Cis solution (Cisplatin-TEVA, Pharmachemie B.V., 0.5 mg/ml) was immobilized on the 
 C60 fullerene according to the protocol developed by our research group (Prylutskyy 
et al. 2015). The initial solution of  C60FAS (final concentration 0.15 mg/ml) and Cis (final 
concentration 0.15 mg/ml) was mixed in 1:1 volume ratio. Afterward, the mixture was 
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treated for 20  min in ultrasonic disperser and, next, subjected to overnight magnetic 
stirring at the room temperature.
Dox (Doxorubicin-TEVA, Pharmachemie B.V., lyophilized powder, 10  mg) was dis-
solved in saline to obtain a final concentration of 0.15  mg/ml. It was immobilized on 
the  C60 fullerene according to a previously described protocol (Prylutskyy et  al. 2014, 
2015). Specifically,  C60FAS (final concentration 0.15 mg/ml) and Dox (final concentra-
tion 0.15 mg/ml) were mixed in 1:2 volume ratio, and the resulting mixture was treated 
for 20 min in the ultrasonic disperser, and then, it was subjected to overnight magnetic 
stirring at the room temperature.
Simulation
The geometric structures for CYP (3tis—crystal structure of the complex between 
human CYP 3A4 and desthiazolylmethyloxycarbonyl ritonavir) and Toll-like recep-
tors (TLRs) (2z7x—crystal structure of the TLR1–TLR2 heterodimer, Homo sapi-
ens, Eptatretus burger; 4g8a—crystal structure of human TLR4 polymorphic variants, 
D299G and T399I) from the PDB base were used in calculations.
Computational methods such as docking and molecular dynamics (MD) simulations 
were applied. We used an algorithm of systematic docking (SDOCK+) implemented in 
QXP docking software, which has shown a higher reproducibility of compound confor-
mation with a minimum Root mean square deviation (Rmsd) in comparison with the 
crystallographic data (Warren et al. 2006). The maximum number of SDOCK+ routine 
steps was set to 200, and the 10 best protein (target)-C60 fullerene complexes, based on 
built-in QXP scoring function (McMartin and Bohacek 1997), were retained for each 
compound. The optimal position of obtained complexes was selected based on their 
overall energy.
Molecular dynamics simulation was performed for up to 25 ps to evaluate the stability 
of protein (target)–C60 fullerene complexes. For the calculation, we used NPA algorithm 
(Sturgeon and Laird 2000). The above method is one of the most accurate and sensi-
tive methods, and it generates true ensemble trajectories (Bond et al. 1999). Within the 
calculation, the next main parameters used were temperature (in K)—300; pressure (in 
kPa)—100; water molecules treated as rigid bodies.
Cell isolation
Four healthy adult men aged 21 ±  2  years were recruited to participate in the study. 
Approval was obtained from the ethical committee of Taras Shevchenko National Uni-
versity of Kyiv, and informed consent was obtained from all subjects before the com-
mencement of the study.
Fresh blood (20 ml) was obtained from volunteers and mixed with 50 μl of preserv-
ative-free heparin (Hospira, UK). Sterile dextran was added to a final concentration of 
0.6%, and the cells were allowed to settle at 37 °C until the red cells had sedimented. The 
buffy coat was then removed, washed in Hanks’ buffered salt solution, and then resus-
pended in RPMI 1640 medium containing 20% fetal calf serum(FCS), penicillin (50 U/
ml), and streptomycin (50 μg/mL) (Evans et al. 1996).
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Cell line
Human myeloid lineage cells U937 were kindly supplied by the Bank of Cell Cultures and 
Transplantable Experimental Tumors of R.E. Kavetsky Institute of Experimental Pathol-
ogy, Oncology and Radiobiology of NAS of Ukraine (Kyiv, Ukraine). Cells were cultured 
in vitro in Dulbecco-modified Eagle medium (DMEM, Sigma, USA) supplemented with 
10% fetal calf serum (FCS), penicillin (100 U/ml), and streptomycin (100 μg/ml) at 37 °C 
in 5%  CO2.
Cell incubation with  C60 fullerene, Cis, Dox, and their nanocomplexes
Prior to the metabolism assays, 200  µl of cell suspension in RPMI 1640 medium or 
200  µl of heparinized whole blood was treated with  C60 fullerene (final concentration 
0.15 mg/ml), Cis (final concentration 0.15 mg/ml), Dox (final concentration 0.15 mg/ml), 
and nanocomplex of  C60 fullerene with Cis (mixed in 1:1 volume ratio) or Dox (mixed in 
1:2 volume ratio) for 30 min.
Nitrite assay
Nitrite-level determination was performed to evaluate NO release into the conditioned 
media of human peripheral blood monocytes and granulocytes as described earlier (Neil 
2009; Skivka et al. 2013). In brief, after 24 h of cultivation, the culture supernatants were 
collected, and the nitrite concentration in each supernatant was assayed by the Griess 
reaction. Equal volumes of 2% sulfanilamide in 10% phosphoric acid and 0.2% naphthy-
lethylene diamine dihydrochloride were mixed to prepare the Griess reagent. The rea-
gent (100 μl) was added to equal volumes of the supernatant, and the mixture was then 
incubated for 30 min at room temperature in the dark. The A550 of the formed chromo-
phore was measured using a plate reader. The nitrite content was calculated with sodium 
nitrite as a standard. Each sample was assayed for nitrite in triplicate. Each value was 
divided by the number of viable cells and expressed as nitrite level per  106 cells. The 
mean value and SD were calculated with normalized values.
Intracellular ROS assay
Reactive oxygen species (ROS) levels were measured using 2′7′-dichlorodihydro-fluo-
rescein diacetate (carboxy-H2DCFDA, Invitrogen) as previously described (Skivka et al. 
2013). In brief, heparinized whole blood was incubated with PBS containing 10 μM car-
boxy-H2DCFDA for 30 min at 37  °C to measure ROS production by peripheral blood 
monocytes and granulocytes. A short recovery time was allowed for the cellular esterases 
to hydrolyze the acetoxymethyl ester or acetate groups and render the dye responsive to 
oxidation. Erythrocytes were lysed with lysis buffer. The cells were then transferred to 
polystyrene tubes with cell-strainer caps (Falcon, Becton–Dickinson, USA) and analyzed 
with flow cytometry (excitation: 488  nm; emission: 525  nm). Only living cells, gated 
according to scatter parameters, were used for the analysis. Granulocytes or monocytes 
were gated according to forward and side scatters. Phorbol 12-myristate 13-acetate 
(PMA) (Sigma-Aldrich) was used to evaluate nonspecific reactivity reserve in phago-
cytes (Shapiro et al. 2011; Skivka et al. 2015). Reactivity reserve was characterized by the 
modulation coefficient (MC) that was calculated by the following formula:
MC = ((S − B)/B× 100),
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where S is the ROS value in probes stimulated with PMA in vitro, and B is ROS value in 
unstimulated probes (basal value).
Phagocytosis assay
The flow cytometry phagocytosis assay was performed as previously described (Skivka 
et  al. 2013). In brief, the fluorescein isothiocyanate(FITC)-labeled heat-inactivated 
Staphylococcus aureus Cowan I bacteria (collected by the Department of Microbiology 
and General Immunology of Taras Shevchenko National University of Kyiv) at the con-
centration of 1 × 107 cells/ml in the volume of 5 μl were added to heparinized whole 
blood. All samples were incubated at 37 °C for 30 min. At the end of the assay, phagocy-
tosis was arrested by the addition of cold stop solution (PBS with 0.02% EDTA and 0.04% 
paraformaldehyde). Erythrocytes were lysed with lysis buffer. Results were assessed 
using FACSCalibur flow cytometer and CellQuest software (Becton–Dickinson, USA). 
Granulocytes or monocytes were gated according to forward and side scatters. The 
results were registered as the percentage of cells emitting fluorescence after a defined 
culture period (phagocytosis percentage, PP) and as phagocytosis index (PI) that repre-
sents the mean fluorescence per one phagocytic cell (engulfed bacteria by one cell).
Determination of arginase activity
Arginase activity was measured in cell lysates by standard colorimetric method with 
some modifications (Skivka et al. 2013). In brief, 100 μl of 0.1% Triton X-100 and 100 μl 
of 50  mMTris-HCl (pH 7.5), containing 10 mM  MnCl2, were sequentially added to 
cell samples. Phagocyte arginase was then activated by heating of the mixture at 56 °C 
for 7  min. The reaction of l-arginine hydrolysis by arginase was carried out by incu-
bation of the mixture containing activated arginase, with 100  μl of l-arginine (0.5  M; 
pH 9.7) at 37  °C for 2 h, and was stopped by the addition of 800 μl of the mixture of 
acidic solution  (H2SO4:H3PO4:H2O  =  1:3:7). For colorimetric determination of urea, 
α-isonitrosopropiophenone (40 μl, 9% solution in ethanol) was added, and the mixture 
was incubated at 95 °C for 30 min and then at 4 °C for 30 min. The urea concentration 
was determined spectrophotometrically at 540 nm with the use of a microplate reader. 
Each condition was tested in triplicate and the experiments were repeated at least three 
times. Each value was divided by the number of viable cells and expressed as urea level/h 
per  106 cells. The mean value and SD were calculated with normalized values.
Cell death assay
Apoptosis was assessed by staining cells with Annexin V-FITC and counterstaining with 
propidium iodide (PI) with the use Annexin V-FITC Apoptosis Detection Kit (Dojin-
doEUGmbH, Munich, Germany) according to the manufacturer’s instructions. In brief, 
2 ×  105 cells were placed into wells of a 96-well flat-bottomed plate and were either 
treated with  C60 fullerene, Cis, Dox and their nanocomplexes at maximum concentra-
tion (0.15 mg/ml) for 24 h. Untreated cells were used as a control. Afterward cells were 
washed twice with PBS and stained with 5 μl Annexin V-FITC and 5 μl PI in binding 
buffer for 10 min at room temperature in the dark. Cells from each sample were then 
analyzed by FacsCalibur flow cytometer (BD Biosciences). The data were analyzed using 
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CELLQuest software (BD). PI detects cells that have lost CPM integrity (i.e., necrotic 
and secondary necrotic cells), whereas Annexin V detects early apoptotic cells.
Statistical analysis
All experimental results are reported as mean ± SD. Statistical significance of the results 
was determined by t test (unpaired, two-tailed) and the nonparametric Mann–Whitney 
test, comparing two groups of independent samples. Means were compared, and differ-
ences were considered significant at p values of 0.05 or less.
Results and discussion
Phagocytes play a crucial role in antitumor immunity. Modulation of their metabolism 
is involved in anticancer effect of conventional anticancer preparations (Banciu et  al. 
2008; Wong et al. 2014) and can be considered as one of the mechanisms of  C60 fuller-
ene antineoplastic action.  C60 fullerene can affect phagocyte metabolism by activation 
of membrane receptor followed (or no) by the endocytosis and/or by interaction with 
intracellular receptive structures after passive diffusion. Entry pathways of  C60 fullerene-
based nanoformulations shift from passive diffusion to receptor-mediated endocytosis 
with increasing particle size (Russ et al. 2016; Zhang et al. 2011). As we reported previ-
ously (Prylutskyy et  al. 2013, 2014; Ritter et  al. 2015), the probe microscopy revealed 
in our preparations randomly arranged individual  C60 molecules with a diameter 
of ~ 0.7 nm and their bulk sphere-like aggregates with a height of 2–100 nm in  C60FAS. 
Therefore,  C60 fullerenes and their nanocomplexes with anticancer drugs can exert addi-
tive membrane-dependent and direct intracellular effect on phagocyte metabolism. It 
was important to investigate the effect of  C60 fullerenes and their nanocomplexes with 
anticancer drugs on different metabolic reactions of nonsensitized human peripheral 
blood phagocytes as well as myeloid leukemia cells U937, and revealed potential recep-
tive membrane and intracellular structures, which could be involved in such effect.
Molecular docking analysis
The molecular docking approach allows simulating the behavior of small molecules such 
as  C60 fullerenes and their nanocomplexes with anticancer drugs in the binding sites of 
target cells. It also gives us an opportunity to predict the effect of such small molecules 
on metabolic processes in cells (Hurmach et al. 2014; Guedes et al. 2014).
Majority of metabolic phagocyte functions depends on the activation of pattern-rec-
ognition receptors, among which TLRs are most important. TLR signaling is involved 
in activation/regulation such fundamental phagocyte functions as phagocytosis, oxygen-
dependent and oxygen independent cytotoxicity, arginine metabolism, antigen pres-
entation, cytokine synthesis etc. (Parker et  al. 2005; McCoy and O’Neill 2008). Some 
TLRs are considered as a binding site for  C60 fullerene (Turabekova et  al. 2014). Tak-
ing into account the profound influence of  C60 fullerene-based nanoformulations on cell 
oxidative metabolism, one of its significant intracellular targets can be the CYP—a key 
component of the monooxygenase system. Unlike other hemoproteins having in cell 
usually one activity and well-defined function, CYP alongside monooxygenase activ-
ity can exhibit oxidase one, generating such ROS as superoxide and hydroxyl radicals, 
hydrogen peroxide. Poor coupling of the CYP catalytic cycles results in continuous ROS 
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generation. CYP is reported to produce 12(S)-hydroxyheptadeca-5Z,8E,10E-trienoic 
acid (12-HHT) that is overexpressed in classically activated macrophages (Zangar et al. 
2004; Frömel et al. 2013).
Cytochrome p450
The active site for the majority of the monoxidation reactions, which CYP enzymes cata-
lyze, contains a heme group during the catalytic processes (Meunier et  al. 2004). It is 
known that CYP3A4 can accommodate multiple substrates owing to the large size of 
the active site [(500–1532) Å] (Cui et al. 2013). So, in both cases  C60 fullerene can fill in 
the binding site, interact with a large number of amino acids and create cation π-system 
with cofactor. For example, in the case of PDB 3tis structure,  C60 fullerene involved in 
the stacking interaction with Phe 304 and Phe 108 (Fig. 1).
The docking and MD results indicate that  C60 fullerene forms stable complex with 
CYP: the respective free energy of complexation is −  54.4  kJ/mol after docking and 
−  47.5  kJ/mol after MD simulation. The energy of steric clashes for  C60 fullerene is 
higher after MD simulation than that after docking: it means that  C60 fullerene–CYP 
complex after MD simulation is more rigid, despite that its overall energy is less (18.8 kJ/
mol after docking and 25.7  kJ/mol after MD simulation). One can assume that this is 
due to changes in the binding site. Furthermore, the distance between cofactor and  C60 
fullerene decreased: it equals to 5.4 Å after docking and 4.52 Å after MD simulation. At 
the same time, the Rmsd value for  C60 fullerene is not significant: it equals to 0.56 Å (in 
turn the Rmsd value of protein is 2.53 Å). As a result  C60 fullerene deepens into the bind-
ing site and gets stuck among some amino acids (e.g., Phe 108 and Phe 304 (Fig. 1); Rmsd 
values are 3.5 and 1.2 Å, respectively).
TLRs
Based on previous data (Turabekova et al. 2014), docking and MD simulation were car-
ried out using TLR1/TLR2 [Fig. 2; we investigated the binding of  C60 fullerene in extra-
cellular domains (ECDs)] and TLR4 (Fig. 3; we investigated the binding of  C60 fullerene 
in MD2 domain).
Fig. 1 Model of  C60 fullerene-3tis binding: A docking, B MD simulation
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Docking and MD results showed that numerous Phe and Tyr residues easily create 
π–π interactions, while other amino acids (e.g., Leu, Ile, Ala, Val, and Pro) form lipo-
philic contacts with the sidewalls of  C60 fullerene (Figs. 2, 3, 4, 5). In the case of binding 
of  C60 fullerene with TLR1/TLR2/ECD and TLR4/MD-2, significant mobilities of protein 
are observed (much larger than that for the previous object): 5.2 and 4.6 Å, respectively. 
The obtained models were also characterized by a large energies of  C60 fullerene–TLR 
Fig. 2 C60 fullerene–TLR1/TLR2/ECD-bound structure
Fig. 3 C60 fullerene–TLR4/MD-2-bound structure
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complexes both after docking (free energies of complexation: − 19.2 and − 50.9 kJ/mol, 
respectively) and MD simulation (free energy of complexation − 26.8 and − 50.6 kJ/mol, 
respectively). The binding of  C60 fullerene with TLR1/TLR2/ECDs occurs in the outer 
part of ECDs (Rmsd 6.7 Å) and, consequently, there is formation of new stronger stack-
ing interactions with Phe 209 and Tyr 300 (Figs. 2, 4). The binding of  C60 fullerene with 
TLR4/MD-2 is characterized by complete filling of the hydrophobic pocket of MD-2 
(Figs. 3, 5) and the formation of a significant number of stacking interactions (e.g., with 
Phe 119, Phe 76 and Phe 104; Fig. 5B). This change of binding site is associated with sig-
nificant mobility of interacting components: Rmsd value for protein is 4.6 Å, and for  C60 
fullerene—5.3 Å.
Thus, one can suggest that the formation of complexes of  C60 fullerene, both with CYP 
and different parts of TLR1/TLR2 and TLR4, is potentially possible. At the same time, 
the calculated energy and geometrical parameters for the  C60 fullerene–CYP complex 
indicate its greater stability compared with the probable  C60 fullerene–TLR complexes.
Taking into account the results of the performed docking analysis, it was reasonable 
to investigate the ability of  C60 fullerene and its nanocomplexes with anticancer drugs to 
modulate phagocyte metabolic processes associated with CYP and TLR signaling: ROS 
and reactive nitrogen species (RNS) generations, arginase activity, and phagocytosis.
Fig. 4 C60 fullerene–TLR1/TLR2/ECD-bound structure: A docking, B MD simulation
Fig. 5 C60 fullerene–TLR4/MD-2-bound structure: A docking, B MD simulation
Page 11 of 22Skivka et al. Cancer Nano             (2018) 9:8 
Peripheral blood phagocyte ROS generation
C60 fullerenes are most frequently positioned as “free radical sponges” and antioxi-
dants due to their ability to absorb electrons (Gharbi et al. 2005; Prylutska et al. 2008). 
However, depending on the circumstances,  C60 fullerenes are capable of both quench-
ing ROS and induce their generation with or without photoexcitation (Dellinger et al. 
2013; Scharff et al. 2004; Markovic and Trajkovic 2008; Prylutska et al. 2010). Moreo-
ver, spontaneous induction of ROS generation by  C60 fullerenes plays a pivotal role in 
their toxic effect on eukaryotic normal and malignant cells.  C60 fullerenes and their 
derivatives stimulate oxidative metabolism in erythrocytes and fibroblasts, malignant 
lymphocytes and epithelial cells, and endothelial cells and macrophages (Trpkovic et al. 
2012). Ershova et  al. (2016) reported about complex time-dependent changes in ROS 
levels in cells treated with  C60 fullerene derivatives. They differentiate between “early” 
(from 15 min to 3 h) and “late” (24 h) responses to  C60 fullerene exposure. Fluorescence 
microscopy in these experiments revealed that the early response is not associated with 
 C60 fullerene penetration into the cytoplasm and is accompanied by the increase of ROS 
generation within the first 15–30 min on the cell surface. The late response in turn is 
associated with the accumulation of nanoparticles inside the cells, and includes transi-
tory (within 1–2 h after the treatment) decrease of ROS generation followed by the sec-
ondary increase of ROS levels after the 24 h exposure.
There are two main sources of ROS in phagocytes: NADPH oxidase (NOX) and a 
number of cellular enzymes such as CYP and xanthine oxidase that can localize in cyto-
sol, mitochondria, peroxisomes etc. (Dupré-Crochet et  al. 2013). ROS production can 
be induced by the activation of TLRs 1, 2, 4 and 9. TLR-associated ROS generation pri-
marily depends on NOX signaling pathway, and is associated with the cell surface. In 
addition, engagement of TLRs 1, 2 and 4 leads to the recruitment of mitochondria to 
phagosome followed by the activation of ROS generation in these organelles (West et al. 
2011; Fagundes-Netto et al. 2013).
In our experiments, we investigated the effects of  C60 fullerenes and their nanocom-
plexes with anticancer drugs Cis and Dox on intracellular ROS generation of nonsen-
sitized human peripheral blood phagocytes in buffy coat. The treatment exposure 
time was 30 min. It suggests the effect of nanoformulations on ROS generation mainly 
through the interaction with membrane-associated receptive structures. In addition to 
the assessment of the effect of studied preparations on basic level of phagocyte intracel-
lular oxidative metabolism, we also examined the so-called nonspecific reactivity reserve 
of the investigated function. For this purpose, cells were additionally treated with PMA 
that is reported to stimulate ROS generation (Campo et al. 2009). PMA activates NOX 
assembly in the plasma membrane, and can potentially synergize with the effect of nano-
formulations (Dupré-Crochet et al. 2013). Flow cytometry method allowed us to analyze 
intracellular oxidative metabolism of granulocytes and monocytes separately by gating 
according to forward and side scatters.
The treatment of peripheral blood phagocytes with all studied preparations resulted in 
sharp increase of intracellular ROS generation in these cells (Fig. 6). Cis and Dox caused 
more than 15-fold increase in the production of ROS by phagocytes. Our results are 
consistent with numerous literature data. Approximately half of FDA-approved antican-
cer drugs (including Dox and Cis) are known to produce ROS that are critically involved 
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in toxic side effects of these drugs (Keeney et al. 2015). Reactivity reserve in cells treated 
with anticancer drugs in response to PMA was absent. It indicates maximal degrees of 
this function activation and oxidative stress development that threaten the cell viability 
(Fig. 6).  C60 fullerenes caused eightfold increase in ROS generation by phagocytes. We 
registered the reactivity reserve in these cell samples. It indicates the less ROS-mediated 
toxicity of  C60 fullerenes as compared to cytotoxic agents. Reactivity reserve of intracel-
lular oxidative metabolism after the treatment with  C60 fullerenes was greater in granu-
locytes than in monocytes as evidenced by MC values 89.7 and 25.8, respectively (Fig. 6a 
and b). This suggests that the granulocytes better tolerated treatment with  C60 fuller-
enes. The granulocytes are terminally differentiated cells. Unlike neutrophils, circulating 
monocytes are less mature progenitor cells whose differentiation is completed in tissues 
(Dupré-Crochet et al. 2013; Rivera et al. 2016). In addition, granulocytes have only few 
Fig. 6 The effect of  C60 fullerenes and their nanocomplexes with anticancer drugs Cis and Dox on intracel-
lular ROS generation in nonsensitized human peripheral blood granulocytes (a) and monocytes (b). Whole 
blood samples were treated with mentioned preparations for 30 min, then were stained with carboxy-
H2DCFDA (see “Methods”). The fluorescence intensities of 10.000 cells were then analyzed by BD-FACS 
Calibur. All results are expressed as mean ± SD of three independent experiments. *p < 0.05 compared to 
basal level of ROS generation in control; **p < 0.01 compared to basal level of ROS generation in control; 
***p < 0.001 compared to basal level of ROS generation in control; #p < 0.05 compared to corresponding cells 
without treatment with PMA; §p < 0.05 compared to cells treated with Cis alone, as analyzed by unpaired t 
test
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mitochondria (Dupré-Crochet et al. 2013; Dan Dunn et al. 2015), and their contribution 
to the overall ROS production is minimal. Therefore, restricted mitochondria network 
can be another reason of better granulocyte tolerability. In mononuclear phagocytes, 
mitochondrial ROS generations are an important part of total intracellular oxidative 
metabolism. Probably, this fact along with immature state makes monocytes to be more 
vulnerable to the effect of  C60 fullerenes. The complexation of Dox with  C60 fullerene did 
not affect its stimulatory action on phagocyte oxidative metabolism. Whereas the com-
plexation of Cis with  C60 fullerene leads to the downregulation of its stimulatory effect 
on intracellular ROS generation.
Thus,  C60 fullerenes both when used alone and in nanocomplexes with anticancer 
drugs strongly induce intracellular ROS generation in peripheral blood phagocytes, and 
are capable to downregulate pro-oxidant activity of Cis.
Peripheral blood phagocyte NO production
Generation of RNS is TLR-dependent metabolic process and is associated with NFκB 
activation (Parker et al. 2005; McCoy and O’Neill 2008). In addition, RNS synthesis is 
adversely regulated by oxidative stress (Singh et al. 2016) and therefore is related to CYP 
activation. We characterized the RNS generation by the level of nitrites (Griess reaction) 
in culture medium of cells treated with  C60 fullerenes and their nanocomplexes with Cis 
and Dox. The Griess reaction is the most frequently used analytical approach to quanti-
tate the major metabolites of NO, i.e., nitrite and nitrate, in a variety of biological fluids 
(Tsikas 2007). Nitrite production was analyzed in total pool of peripheral blood phago-
cytes contained in buffy coat. In our experiments, treatment of human phagocytes with 
Cis and Dox resulted in moderate decrease of nitrite level (Fig. 7).
Cis and Dox are reported to downregulate inducible nitric oxide synthase (iNOS) 
expression followed by the decrease in RNS production by affected cells. As the 
Fig. 7 The effect of  C60 fullerenes and their nanocomplexes with anticancer drugs Cis and Dox on RNS 
generation in nonsensitized human peripheral blood phagocytes. Phagocytes in buffy coat were treated with 
mentioned preparations for 30 min, then RNS generation was analyzed in Griess reaction (see “Methods”). 
All results are expressed as mean ± SD of three independent experiments. *p < 0.05 compared to control; 
**p < 0.01 compared to control; #p < 0.05 compared to cells treated with Dox alone; §§p < 0.01 compared to 
cells treated with Cis alone, as analyzed by unpaired t test
Page 14 of 22Skivka et al. Cancer Nano             (2018) 9:8 
induction of ROS generation is a one of the mechanism of action of these anticancer 
drugs (Chtourou et al. 2015; Wang et al. 2016), an oxidative stress can be one of the rea-
sons of their negative effect on RNS production.  C60 fullerenes significantly downregu-
lated RNS generation. Similar observations have been published by Huang et al. (2008). 
This research group revealed that nonfunctionalized  C60 fullerene suppresses the release 
of NO by macrophages RAW 264.7. Complexation of Dox with  C60 fullerene leads to 
further moderate reduction of RNS production by phagocytes. In the case of  C60 + Cis 
nanocomplex, the RNS production was extremely low (by 7 times compared with cells 
treated with Cis alone and by 6 times compared with untreated cells). One of the prob-
able reasons for the reduction of RNS synthesis by the treated phagocytes can be oxida-
tive burst.
Peripheral blood phagocyte arginase activity
Arginase converts l-arginine into l-ornithine (precursor of proline and polyamines) and 
urea. iNOS and arginase can compete for the same substrate l-arginine. Overexpressed 
arginase can affect iNOS activity and vice versa. Increase in phagocyte arginase activ-
ity is one of the features of alternatively activated cells participating in tissue remod-
eling and the resolution of inflammation. Whereas the reduction of arginine metabolism 
through arginase activity along with iNOS activation is a sign of classical phagocyte met-
abolic profile, key aspect of the inflammation (Locati et al. 2013; Okabe and Medzhitov 
2016; Egners et  al. 2016). Arginine metabolism with arginase is associated with TLRs 
activation (Parker et  al. 2005; Turabekova et  al. 2014). The impact of  C60 fullerene (as 
well as antineoplastic drugs) on arginase activity is virtually not explored. In our experi-
ments,  C60 fullerene when used alone did not affect this phagocyte metabolic process 
(Fig. 8).
Fig. 8 The effect of  C60 fullerenes and their nanocomplexes with anticancer drugs Cis and Dox on argin-
ase activity of nonsensitized human peripheral blood phagocytes. Phagocytes in buffy coat were treated 
with mentioned preparations for 30 min, then arginase activity was analyzed by colorimetric method (see 
“Methods”). All results are expressed as mean ± SD of three independent experiments. *p < 0.05 compared to 
control, as analyzed by unpaired t test
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Dox slightly downregulated phagocyte arginase activity. Complexation of Dox with  C60 
fullerene abrogated its inhibitory effect on phagocyte arginase activity. Cis used alone as 
well as in the nanocomplex with  C60 fullerene did not affect phagocyte arginase activity. 
The ability of  C60 fullerene to abrogate pro-inflammatory polarization of arginine metab-
olism in phagocytes caused by Dox can facilitate the reduction of cytotoxic side effect of 
the drugs.
Peripheral blood phagocyte endocytosis
Endocytosis (phagocytosis of solid particles and pinocytosis) is an essential part of 
phagocyte metabolism. Endocytosis is regulated by TLRs activation and is associated 
with ROS generation (Guedes et al. 2014; McCoy and O’Neill 2008; Amiel et al. 2009). 
The engulfment machinery differs in mononuclear (monocytes, macrophages, dendritic 
cells) and polymorphonuclear (neutrophils or granulocytes) phagocytes. In addition, 
phagocytosis plays different roles for the metabolic profile of mono- and polymorpho-
nuclear cells. In neutrophils, phagocytosis is often associated with netosis and inflam-
mation (Silvestre-Roig et  al. 2016). In monocytes/macrophages, phagocytosis can be 
associated with inflammation resolution and anti-inflammatory (alternative) metabolic 
profile (Soehnlein and Lindbom 2010). Treatment with all investigated preparations 
did not affect significantly the number of phagocytizing granulocytes in tested probes 
(phagocytosis percentage) (Fig. 9a).
Fig. 9 The effect of  C60 fullerenes and their nanocomplexes with anticancer drugs Cis and Dox on phago-
cytic activity of nonsensitized human peripheral blood granulocytes (a, c) and monocytes (b, d). Whole blood 
samples were treated with mentioned preparations for 30 min, then phagocytic activity was analyzed by 
flow cytometry (see “Methods”). All results are expressed as mean ± SD of three independent experiments. 
*p < 0.05 compared to control, **p < 0.01 compared to control; ***p < 0.001 compared to control; #p < 0.05 
compared to cells treated with Dox alone; ##p < 0.01 compared to cells treated with Dox alone; §p < 0.05 
compared to cells treated with Cis alone, as analyzed by unpaired t test
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Whereas the proportion of phagocytizing monocytic cells in analyzed pool was 
increased after the treatment with Dox and  C60 fullerene used alone as well as with 
 C60  +  Dox. All tested substance influenced phagocytosis intensity in monocytes and 
granulocytes.  C60 fullerene used alone stimulated phagocyte engulfment intensity. PIs 
in treated phagocytes were significantly higher than that in untreated cells: 3.7 times for 
granulocytes and 1.6 times for monocytes (Fig. 9c and d). It is noteworthy that phagocy-
tosis intensity in monocytes and granulocytes was characterized by significant individ-
ual variability that may result from nanoparticle size heterogeneity. Dox used alone also 
increased intensities of monocyte and granulocyte phagocytosis. However, its complexa-
tion with  C60 fullerene abolished this effect. Cis used alone and in the nanocomplex with 
 C60 fullerene did not affect phagocyte endocytosis intensity.
U937 ROS generation
As mentioned above, we observed the dramatic effect of  C60 fullerenes and their nano-
complexes with anticancer drugs on intracellular ROS generation by peripheral blood 
phagocytes. Induction of ROS generation is considered as one of the mechanism of 
cytotoxic effect of  C60 fullerenes (Santos et al. 2014; Zhang et al. 2015; Yu et al. 2015). 
Recently, activating ROS generation has become a promising approach for selective can-
cer treatment (Fruehauf and Meyskens 2007; Tomasetti et al. 2015). Tumor cells exhibit 
higher basal levels of  ROS than normal cells. The intrinsic ROS stress is also charac-
teristic for leukemic cells (Testa et al. 2016). This metabolic feature makes them more 
vulnerable to damage by further ROS insults induced by exogenous agents, whereas 
nonmalignant cells better tolerate the oxidative stress (Sun et  al. 2013). It gave us the 
reason to estimate the effect of  C60 fullerenes and their nanocomplexes with antican-
cer drugs on intracellular ROS generation phagocytic cells. To this end, we used U937 
cell line. U937 is one of the most widely used myeloid cell lines (Baek et al. 2009). U937 
cells of histiocytic lymphoma origin are arrested in a promonocyte/monocyte stage of 
differentiation (Abrink et al. 1994). A genetic analysis by Strefford et al. (2001) showed 
that U937 bears the t(10;11)(p13;q14) translocation. This results in a fusion between the 
MLLT10 (myeloid/lymphoid or mixed-lineage leukemia) gene and the Ap-3-like clath-
rin assembly protein PICALM (Clathrin assembly lymphoid myeloid leukemia), which is 
likely important for the tumorous nature of the cell line. Treatment exposure was 24 h. 
It suggests that the effect of nanoformulation could be mediated through the interac-
tion with both membrane-associated and intracellular receptive structures (Ershova 
et al. 2016). Intracellular ROS levels in U937 cells, as indicated by fluorescence intensity, 
significantly increased in response to the treatment with  C60 fullerenes and their nano-
complexes with anticancer drugs (Fig. 10). Oxidative stress caused by the treatment with 
mentioned preparations was more pronounced in transformed phagocytic cells (U937) 
than in normal peripheral blood phagocytes (see Fig. 6). The level of intracellular ROS in 
U937 cells after the treatment with  C60 fullerenes used alone was 1.8 times higher than 
that in treated circulating monocytes. As shown in Fig. 6, the complexation of Cis with 
 C60 fullerene caused the downregulation of its stimulatory effect on intracellular ROS 
production in circulating phagocytes.
Unlike, the complexation both anticancer drugs with  C60 fullerene did not influence 
their pro-oxidant effect on transformed phagocytes.
Page 17 of 22Skivka et al. Cancer Nano             (2018) 9:8 
Thus,  C60 fullerenes used alone and in nanocomplexes with anticancer drugs caused 
dramatic increase of intracellular ROS generation in transformed phagocytes. As men-
tioned above, U937 cells represent the malignantly transformed myeloid cells that are 
arrested in a promonocyte/monocyte stage. Thus, these cells have an even more imma-
ture phenotypes in comparison with circulating normal monocytes, which turned out 
being more sensitive to the pro-oxidant effect of nanoformulations than neutrophils-
differentiated mature cells. These results allowed us to speculate that immature state and 
increased basal ROS level make malignantly transformed cells more receptive to pro-
oxidant effects of  C60 fullerenes and their complexes, and potentially can be the reasons 
of increased cytotoxicity of nanoformulations toward transformed cells.
Toxic effects of  C60 fullerene and its nanocomplexes with anticancer drugs Cis and Dox 
on normal and malignant phagocytes
To investigate the cause–effect relationship between pro-oxidant activity and cytotox-
icity of  C60 fullerenes and their nanocomplexes with anticancer drugs toward normal 
and transformed phagocytes, Annexin V/PI double staining of these cells treated with 
mentioned compounds was conducted. As shown in Fig. 11, the total number of dead 
normal monocytes after the treatment with  C60 fullerenes was 6.7% vs 11.8% in the case 
of U937 cells. Sensitivity of transformed promonocytes/monocytes to anticancer drug-
mediated death was also higher than that in normal monocytic cells. The complexation 
of Cis with  C60 fullerenes resulted in slight increase in the death rate in transformed 
phagocytes but not in normal phagocytic cells compared with the cells treated with Cis 
alone.  C60 fullerenes being used in the nanocomplex with anticancer drugs influenced 
the mode of cell death induced by Cis and Dox. Annexin V-FITC/PI assay allows differ-
entiating between early apoptotic cells (An+ PI−), late apoptotic cells (An+ PI+), and 
necrotic cells (An− PI+). In phagocytes treated with anticancer drugs used alone, we 
Fig. 10 The effect of  C60 fullerenes and their nanocomplexes with anticancer drugs Cis and Dox on intracel-
lular ROS generation in U937 cells. U937 cells were treated with mentioned preparations for 30 min, then 
were stained with carboxy-H2DCFDA (see “Methods”). The fluorescence intensities of 10,000 cells were then 
analyzed by BD-FACS Calibur. All results are expressed as mean ± SD of three independent experiments. 
*p < 0.05 compared to basal level of ROS generation in control; #p < 0.05 compared to corresponding cells 
without treatment with PMA, as analyzed by unpaired t test
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registered higher necrosis level compared with their counterparts treated with  C60 + Cis 
and  C60  +  Dox nanocomplexes. Apoptosis:necrosis ratio in cell samples treated with 
anticancer drugs was 2:1 (on average), whereas in the cells treated with  C60 + Cis and 
 C60 + Dox nanocomplexes, this ratio was 10:1 (on average).
Conclusions
Thus,  C60 fullerenes modulate phagocyte functions: stimulate phagocytic activity and 
downregulate RNS generation. In addition,  C60 fullerenes can exert direct cytotoxic 
effect on phagocytes, more pronounced in the case of malignant cells. This cytotoxic 
effect is associated with the vigorous induction of intracellular ROS generation. More 
pronounced pro-oxidant effect of  C60 fullerenes was also observed in transformed 
phagocytes. We hypothesize three main reasons for the increased receptivity of trans-
formed cells to pro-oxidant, and thus, cytotoxic effects of nanoformulations. Two of 
Fig. 11 U937 cells (b) are more vulnerable to cytotoxic effect of  C60 fullerenes and their nanocomplexes with 
Cis and Dox compared with normal monocytes (a). Cells were treated with mentioned compounds at the 
concentration of 0.15 mg/ml for 24 h. After culturing, cells were stained with annexinV (AnnV)/propidium 
iodide (PI) and analyzed by flow cytometry. Control: cells were incubated without any additional agents. 
The average values for 4 independent experiments are presented. *p < 0.05 compared with untreated cells; 
#p < 0.05 compared to cells treated with Dox alone; §p < 0.05 compared to cells treated with Cis alone, as 
analyzed by unpaired t test
Page 19 of 22Skivka et al. Cancer Nano             (2018) 9:8 
them are the increased basal level of ROS and the immature state of transformed cells. 
The third reason can be the overexpression of enzymes responsible for metabolism of 
xenobiotics, including CYP (that is characteristic for malignant cells), if one takes into 
account that CYP can be considered as one of the intracellular receptive structures for 
 C60 fullerenes and their nanocomplexes. On the other hand,  C60 fullerenes have the abil-
ity to downregulate pro-oxidant effect of Cis on normal cells. Our results indicate that 
 C60 fullerenes have both pro-oxidant and antioxidant properties. These results are con-
sistent with the observations of other scientific group (Markovic and Trajkovic 2008).
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